Corcept Therapeutics annual free cash flow
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Corcept Therapeutics Free Cash Flow (FCF) History (CORT)
Corcept Therapeutics reported $141.8M in free cash flow for fiscal 2025, a decrease of 27.71% from the previous fiscal year, with a free cash flow margin of 18.62%.
View full Corcept Therapeutics company overviewCorcept Therapeutics free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $141.8M | −$54.3M | −27.71% | +18.62% |
| 2024 | 2024-12-31 | $196.1M | $69.6M | +54.99% | +29.05% |
| 2023 | 2023-12-31 | $126.5M | $6.6M | +5.53% | +26.23% |
| 2022 | 2022-12-31 | $119.9M | −$47.5M | −28.38% | +29.84% |
| 2021 | 2021-12-31 | $167.4M | $16.7M | +11.07% | +45.75% |
| 2020 | 2020-12-31 | $150.7M | $15.7M | +11.63% | +42.59% |
| 2019 | 2019-12-31 | $135.0M | $19.7M | +17.04% | +44.06% |
| 2018 | 2018-12-31 | $115.4M | $54.9M | +90.64% | +45.92% |
| 2017 | 2017-12-31 | $60.5M | $42.3M | +232.56% | +38.01% |
| 2016 | 2016-12-31 | $18.2M | $15.1M | +484.55% | +22.38% |
| 2015 | 2015-12-31 | $3.1M | $30.7M | — | +6.19% |
| 2014 | 2014-12-31 | −$27.6M | $9.6M | — | −103.76% |
| 2013 | 2013-12-31 | −$37.2M | −$1.0M | — | −359.03% |
| 2012 | 2012-12-31 | −$36.2M | −$8.7M | — | −1093.77% |
| 2011 | 2011-12-31 | −$27.4M | — | — | — |
Corcept Therapeutics quarterly free cash flow
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $31.0M | −$13.2M | −29.89% | +12.11% |
| Q1 2026 | 2026-03-31 | −$17.0M | −$21.6M | — | −10.29% |
| Q4 2025 | 2025-12-31 | $38.4M | −$21.5M | −35.94% | +19.00% |
| Q3 2025 | 2025-09-30 | $54.5M | −$17.2M | −23.97% | +26.24% |
| Q2 2025 | 2025-06-30 | $44.2M | $3.5M | +8.51% | +22.75% |
| Q1 2025 | 2025-03-31 | $4.7M | −$19.1M | −80.36% | +2.97% |
| Q4 2024 | 2024-12-31 | $59.9M | $54.4M | +984.05% | +32.95% |
| Q3 2024 | 2024-09-30 | $71.7M | $18.8M | +35.53% | +39.25% |
| Q2 2024 | 2024-06-30 | $40.8M | −$1.4M | −3.35% | +24.89% |
| Q1 2024 | 2024-03-31 | $23.8M | −$2.2M | −8.48% | +16.18% |
| Q4 2023 | 2023-12-31 | $5.5M | −$27.8M | −83.42% | +4.08% |
| Q3 2023 | 2023-09-30 | $52.9M | $19.6M | +58.79% | +42.78% |
| Q2 2023 | 2023-06-30 | $42.2M | $24.2M | +134.08% | +35.84% |
| Q1 2023 | 2023-03-31 | $26.0M | −$9.3M | −26.33% | +24.57% |
| Q4 2022 | 2022-12-31 | $33.4M | −$16.0M | −32.42% | +32.37% |
| Q3 2022 | 2022-09-30 | $33.3M | −$15.2M | −31.41% | +32.73% |
| Q2 2022 | 2022-06-30 | $18.0M | −$26.2M | −59.25% | +17.43% |
| Q1 2022 | 2022-03-31 | $35.2M | $9.9M | +39.29% | +37.61% |
| Q4 2021 | 2021-12-31 | $49.4M | $14.7M | +42.50% | +49.95% |
| Q3 2021 | 2021-09-30 | $48.5M | $18.8M | +63.31% | +50.50% |
| Q2 2021 | 2021-06-30 | $44.2M | −$8.9M | −16.78% | +48.28% |
| Q1 2021 | 2021-03-31 | $25.3M | −$7.9M | −23.87% | +31.84% |
| Q4 2020 | 2020-12-31 | $34.6M | −$13.7M | −28.31% | +40.40% |
| Q3 2020 | 2020-09-30 | $29.7M | −$8.4M | −22.06% | +34.43% |
| Q2 2020 | 2020-06-30 | $53.1M | $28.0M | +111.33% | +60.00% |
| Q1 2020 | 2020-03-31 | $33.2M | $9.8M | +41.85% | +35.63% |
| Q4 2019 | 2019-12-31 | $48.3M | $26.9M | +125.73% | +54.97% |
| Q3 2019 | 2019-09-30 | $38.1M | −$6.3M | −14.21% | +46.80% |
| Q2 2019 | 2019-06-30 | $25.1M | $10.0M | +66.00% | +34.80% |
| Q1 2019 | 2019-03-31 | $23.4M | −$10.9M | −31.81% | +36.13% |
| Q4 2018 | 2018-12-31 | $21.4M | −$3.4M | −13.87% | +32.03% |
| Q3 2018 | 2018-09-30 | $44.5M | $33.6M | +310.03% | +68.99% |
| Q2 2018 | 2018-06-30 | $15.1M | −$220,000 | −1.43% | +24.31% |
| Q1 2018 | 2018-03-31 | $34.4M | $24.9M | +263.49% | +59.58% |
| Q4 2017 | 2017-12-31 | $24.9M | $20.4M | +453.05% | +46.65% |
| Q3 2017 | 2017-09-30 | $10.8M | $2.0M | +22.59% | +25.36% |
| Q2 2017 | 2017-06-30 | $15.4M | $13.8M | +870.81% | +43.22% |
| Q1 2017 | 2017-03-31 | $9.5M | $6.2M | +188.58% | +34.24% |
| Q4 2016 | 2016-12-31 | $4.5M | $348,000 | +8.39% | +18.87% |
| Q3 2016 | 2016-09-30 | $8.8M | $8.0M | +901.70% | +40.71% |
| Q2 2016 | 2016-06-30 | $1.6M | $1.7M | — | +8.03% |
| Q1 2016 | 2016-03-31 | $3.3M | $5.1M | — | +20.39% |
| Q4 2015 | 2015-12-31 | $4.1M | $5.5M | — | +27.70% |
| Q3 2015 | 2015-09-30 | $883,000 | $6.8M | — | +6.66% |
| Q2 2015 | 2015-06-30 | −$139,000 | $8.9M | — | −1.16% |
| Q1 2015 | 2015-03-31 | −$1.8M | $9.4M | — | −17.93% |
| Q4 2014 | 2014-12-31 | −$1.4M | $6.3M | — | −15.57% |
| Q3 2014 | 2014-09-30 | −$5.9M | $2.7M | — | −81.64% |
| Q2 2014 | 2014-06-30 | −$9.0M | $208,000 | — | −154.37% |
| Q1 2014 | 2014-03-31 | −$11.2M | $402,000 | — | −253.58% |
| Q4 2013 | 2013-12-31 | −$7.7M | $1.1M | — | −187.27% |
| Q3 2013 | 2013-09-30 | −$8.7M | $614,000 | — | −329.04% |
| Q2 2013 | 2013-06-30 | −$9.2M | −$1.3M | — | −488.63% |
| Q1 2013 | 2013-03-31 | −$11.6M | −$1.4M | — | −673.97% |
| Q4 2012 | 2012-12-31 | −$8.8M | — | — | −639.07% |
| Q3 2012 | 2012-09-30 | −$9.3M | — | — | −879.72% |
| Q2 2012 | 2012-06-30 | −$7.9M | — | — | −905.83% |
| Q1 2012 | 2012-03-31 | −$10.2M | — | — | — |
Corcept Therapeutics free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $150.7M to $141.8M, a compound annual decline of 1.22%. Corcept Therapeutics's latest reported quarter, Q2 2026, generated $31.0M in free cash flow, a decrease of 29.89% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Corcept Therapeutics source filings ↗Community posts
Corcept receives positive European recommendation for ovarian-cancer therapy
European drug advisers recommended approval of Corcept’s ($CORT) relacorilant, to be marketed as Lifyorli, in combination with nab-paclitaxel for platinum-resistant ovarian cancer. The positive opinion from the Committee for Medicinal Produ ...
